Wearable ECG competition is intensifying with Wellysis, a Samsung spinoff, entering the U.S. market.
Wellysis has obtained FDA clearance for its S-Patch Ex device, which is already available in 14 countries, including the UK, Spain, Italy, Greece, Poland, Australia, Thailand, India, and Korea. The device, equipped with Samsung Electronics' bio-processor, offers accurate ECG waveforms and is intended for use in both home and clinical settings.
Wellysis plans to launch in the U.S. this month through partnerships with service and platform providers.
The S-Patch Ex distinguishes itself with its lightweight design (9g), continuous testing capability, compatibility with mobile devices and watches, and durability (IP55 rating). It has been used by healthcare providers for patients with palpitations and by research institutions to collect ECG data from long COVID patients.
Wellysis aims to provide a patient-centric and physician-friendly ECG solution in the competitive market, offering comfort, ease of use, and accurate information.
Click here to read the original news story.